Argentinian digital health strategy

Digital Health is one of the three pillars for the effective implementation of Universal Health Coverage in Argentina. The Ministry of Health published the National Digital Health Strategy 2018-2024 in order to establish the conceptual guidelines for the design and development of interoperable health information systems as a state policy. The World Health Organization "National eHealth Strategy Toolkit", "Global Strategy on Digital Health" and other international and local evidence and expert recommendations were taken into account. The path to better healthcare involves adopting systems at the point of care, allowing for the primary recording of information and enabling information exchange through real interoperability. In that way, people, technology and processes will synergize to enhance integrated health service networks. In this paper, we describe the plan and the first two years of implementation of the strategy.Fil: Rizzato Lede, Daniel A.. Ministerio de Salud de la Nación; ArgentinaFil: Pedernera, Federico A.. Ministerio de Salud de la Nación; ArgentinaFil: López, Emiliano. Ministerio de Salud de la Nación; ArgentinaFil: Speranza, Cintia D.. Ministerio de Salud de la Nación; ArgentinaFil: Guevel, Carlos Gustavo. Ministerio de Salud de la Nación; ArgentinaFil: Maid, Jesse J.. Ministerio de Salud de la Nación; ArgentinaFil: Mac Culloch, Patricia. Ministerio de Modernización; ArgentinaFil: Rolandi, Florencia. Ministerio de Modernización; ArgentinaFil: Ayala, Fabiana. Ministerio de Modernización; ArgentinaFil: Abadie, Daniel A.. Ministerio de Modernización; ArgentinaFil: Baqué, María I.. Ministerio de Modernización; ArgentinaFil: Gassino, Fernando. Ministerio de Salud de la Nación; Argentina. Hospital Italiano; ArgentinaFil: Campos, Fernando. Hospital Italiano; ArgentinaFil: Kaminker, Diego. No especifíca;Fil: Cejas, Cintia A.. Ministerio de Salud de la Nación; ArgentinaFil: López Osornio, Alejandro. Ministerio de Salud de la Nación; ArgentinaFil: Rubinstein, Adolfo Luis. Ministerio de Salud de la Nación; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentin

Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines

Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.Fil: Isnardi, Carolina A.. No especifíca;Fil: Cerda, Osvaldo L.. No especifíca;Fil: Landi, Margarita. Austral University Hospital; LiberiaFil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Schneeberger, Emilce E.. No especifíca;Fil: Montoro, Claudia Calle. Austral University Hospital; LiberiaFil: Alfaro, María Agustina. No especifíca;Fil: Roldán, Brian M.. No especifíca;Fil: Gómez Vara, Andrea B.. No especifíca;Fil: Giorgis, Pamela. No especifíca;Fil: Ezquer, Roberto Alejandro. No especifíca;Fil: Crespo Rocha, María G. No especifíca;Fil: Reyes Gómez, Camila R.. No especifíca;Fil: de Los Ángeles Correa, Mária. No especifíca;Fil: Rosemffet, Marcos G.. No especifíca;Fil: Abarza, Virginia Carrizo. No especifíca;Fil: Pellet, Santiago Catalan. Austral University Hospital; LiberiaFil: Perandones, Miguel. No especifíca;Fil: Reimundes, Cecilia. Austral University Hospital; LiberiaFil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quintana, Rosana Maris. No especifíca;Fil: de la Vega, María Celina. No especifíca;Fil: Kreplak, Nicolás. No especifíca;Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Maid, Pablo. Austral University Hospital; LiberiaFil: Pons Estel, Guillermo J.. No especifíca;Fil: Citera, Gustavo. No especifíca

Respuesta immune humoral asociada a las vacunas contra SARS-CoV-2 en pacientes con artritis reumatoidea: datos del registro SAR-CoVAC

Introducción: la artritis reumatoidea (AR) y los tratamientos indicados para su manejo pueden afectar la respuesta a la vacuna para SARS-CoV-2. Sin embargo, aún no se cuenta con datos locales. Objetivos: evaluar la respuesta humoral de la vacuna para SARS-CoV-2 y su seguridad en esta población. Materiales y métodos: estudio observacional. Se incluyeron pacientes ≥18 años, con AR ACR/EULAR 2010 que recibieron la vacunación para SARS-CoV-2

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Ablation of Atrial Fibrillation in a Patient with Dilated Cardiomyopathy

This presentation describes a patient of 57 years, hospitalized for progressive congestive heart failure. The electrocardiogram showed atrial fibrillation of high ventricular response and the echocardiogram revealed dilated cardiomyopathy with severe impairment of the left ventricular function and severe mitral regurgitation without organic valvular compromise. Coronary artery disease was ruled out. Radiofrequency ablation was presented as the best alternative for his condition.The patient recovered sinus rhythm, with which he remains since last 2 years, with asymptomatic evolution and improvement of all echocardiographic parameters.  Invasive treatment of atrial fibrillation in patients with dilated cardiomyopathy with suspicion of tachycardiomyopathy represents a difficult and controversial decision.El tratamiento invasivo de la fibrilación auricular en pacientes con miocardiopatía dilatada con sospecha de taquicardiomiopatía representa una decisión difícil y controversial. En esta presentación se describe el caso de un paciente de 57 años, internado por insuficiencia cardíaca congestiva progresiva. En el electrocardiograma se evidenció fibrilación auricular de alta respuesta ventricular y en el ecocardiograma, miocardiopatía dilatada con deterioro grave de la función del ventrículo izquierdo e insuficiencia mitral grave sin compromiso orgánico valvular. Se descartó enfermedad coronaria. Se planteó la ablación por radiofrecuencia como la mejor alternativa para su cuadro

First Argentine Catheter Ablation Registry

La electrofisiología cardíaca ha tenido en los últimos años un desarrollo muy importante dentro del aspecto terapéutico de las arritmias cardíacas gracias a la implementación de procedimientos invasivos como la ablación con catéter de sustratos, focos y circuitos arritmogénicos a través de la aplicación de corriente de radiofrecuencia. El Consejo de Electrofisiología de la Sociedad Argentina de Cardiología decidió realizar un registro de este procedimiento con la participación libre y anónima de los principales laboratorios de electrofisiología de nuestro país.Conocer el número de procedimientos de ablación con catéter, datos epidemiológicos de los pacientes, indicaciones más frecuentes, resultados y complicaciones a través de la información suministrada por los centros participantes en el período estudiado.Material y métodos(Resumen completo en PDF) Objetivos  Se realizó un registro prospectivo y consecutivo de los procedimientos informados desde noviembre de 2007 hasta marzo de 2009 (16 meses). 

Diagnostic Value of Cardiac Magnetic Resonance in Patients with Frequent Ventricular Arrhythmia and Normal Doppler Echocardiography

La arritmia ventricular frecuente (AVF) puede ser una alteración eléctrica primaria, o estar asociada a una cardiopatía. El impacto pronóstico y terapéutico depende  de la presencia de cardiopatía estructural. . El ecocardiograma doppler transtorácico ha sido el estudio complementario más importante para evaluar la presencia de alteraciones estructurales cardíacas. El objetivo de nuestro estudio consiste en determinar la capacidad de la resonancia magnética cardíaca (RMC) para detectar alteraciones estructurales a nivel cardíaco en pacientes con ecocardiograma doppler normal y conocer la incidencia de eventos cardiovasculares adversos en el seguimiento. Se incluyeron 66 pacientes consecutivos con arritmia ventricular frecuente definido como extrasístoles ventriculares > 5000 en un registro de Holter de 24 hs, taquicardia ventricular o muerte súbita resucitada con ecocardiograma doppler normal. A todos los pacientes se les realizó una resonancia magnética cardíaca con protocolo para evaluar miocardiopatías. El 57% de los pacientes presentó alguna alteración estructural, siendo las patologías diagnosticadas más prevalente: la secuela de miocarditis, el miocardio no compactado y la secuela de infarto subendocárdico.  En el seguimiento medio de  24 ± 22 meses, la incidencia de eventos cardiovasculares adversos fue 6.06%. El número de extrasístoles ventriculares fue mayor en aquellos pacientes con resonancia anormal. Este trabajo demuestra que en pacientes con arritmia ventricular frecuente con ecocardiograma doppler normal, la realización de una resonancia magnética cardíaca con gadolinio permite detectar en más de la mitad de los casos alguna alteración estructural.IntroductionFrequent ventricular arrhythmia can be a primary electrical disturbance or may beassociated to cardiomyopathy. The prognostic and therapeutic impact depends onthe presence of structural heart disease. Transthoracic Doppler echocardiographyhas been the most important complementary study to evaluate the presence of cardiacstructural abnormalities.ObjectivesThe aims of this study were to determine the ability of cardiac magnetic resonanceimaging to detect structural heart disease in patients with normal Doppler echocardiogramand to assess the incidence of adverse cardiovascular events during followup.MethodsThe study included 66 consecutive patients with frequent ventricular arrhythmiadefined as > 5000 ventricular extrasystoles in 24-hour Holter monitoring, ventriculartachycardia or resuscitated cardiac respiratory arrest with normal Dopplerechocardiogram. All patients underwent cardiac magnetic resonance imaging to assesscardiomyopathies.ResultsFifty-seven percent of patients had structural heart disease. The most prevalentdiagnosed pathologies were myocarditis sequelae, non-compacted myocardium andsubendocardial infarction scar. At mean follow-up of 24 ± 22 months, the incidenceof adverse cardiovascular events was 6.06 %. The number of ventricular extrasystoleswas higher in patients with abnormal cardiac magnetic resonance.DiscussionThis work demonstrates that in patients with frequent ventricular arrhythmia andnormal Doppler echocardiogram, gadolinium cardiac magnetic resonance imagingcan detect structural heart disease in more than half of the cases. Patients with frequentventricular arrhythmia during Holter monitoring, normal Doppler echocardiogramand mild alterations in the magnetic resonance present low risk of cardiovascularevents

Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Published by Elsevier Ltd.Background: Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods: In this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings: 14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p<0·0001), and population mobility (1·03 per 1% increase in number of visits to grocery and pharmacy stores [1·02-1·05]; p<0·0001 and 1·02 per 1% increase in number of visits to workplaces [1·00-1·03]; p=0·032) were independently associated with higher odds of mortality. Number of hospital beds (0·94 per 1-unit increase per 1000 people [0·88-1·00]; p=0·046), human development index (0·65 per 0·1-unit increase [0·44-0·96]; p=0·032), government response stringency (0·83 per 10-unit increase in containment index [0·74-0·93]; p=0·0018), as well as follow-up time (0·78 per month [0·69-0·88]; p<0·0001) were independently associated with lower odds of mortality. These factors sufficiently explained country-level variations in death attributable to COVID-19 (intraclass correlation coefficient 1·2% [0·1-9·5]; p=0·14). Interpretation: Our findings highlight the importance of environmental and societal factors as potential explanations of the observed regional disparities in COVID-19 outcomes among people with rheumatic disease and lay foundation for a new research agenda to address these disparities.MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]). KDW is supported by the Department of Veterans Affairs and the Rheumatology Research Foundation Scientist Development award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). AD-G is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. RH was supported by the Justus-Liebig University Giessen Clinician Scientist Program in Biomedical Research to work on this registry. JY is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155).info:eu-repo/semantics/publishedVersio

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected